EAN 2020 | Fremanezumab in patients with chronic or episodic migraine

Uwe Reuter, MD, PhD, MBA, Charité – University Medicine Berlin, Berlin, Germany, discusses anti-calcitonin gene-related peptide monoclonal antibodies, in particular fremanezumab and the FOCUS trial (NCT03308968). This study evaluated the efficacy, safety, and tolerability of subcutaneous injections of fremanezumab compared with placebo in patients with chronic migraine or episodic migraine who have responded inadequately to 2 to 4 classes of prior preventive treatments. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).